Beyondspring (BYSI) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
SEED Therapeutics has announced a strategic research collaboration with Eisai Co., Ltd. to develop molecular glue degraders targeting neurodegenerative diseases and cancer, with potential payments up to $1.5 billion plus royalties. Additionally, SEED has initiated a Series A-3 financing round, led by Eisai, raising $24 million to advance their cancer treatment programs and expand their Targeted Protein Degradation (TPD) platform. This move strengthens SEED’s position in developing treatments for diseases with limited options and showcases their growth in the biotech sector, bolstered by prior investments from Eli Lilly and BeyondSpring.
For further insights into BYSI stock, check out TipRanks’ Stock Analysis page.
